DFine competitors

Ms. Karen L. Zaderej is a Chief Executive Officer at AXOGEN, INC. and is based in United States.

Shai Gozani, founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology. He currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Shai has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 2.5 million patients have benefited from the Company’s technology over the past 17 years.Shai has published over 30 peer-reviewed scientific articles and has been awarded over 40 US and international patents. He holds a B.A. degree in Computer Science, a M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. Shai also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.

Michael Els is a Chief Executive Officer at Orthofix and is based in Johannesburg, Gauteng, South Africa.

Dr. Ellison has served as our President and Chief Executive Officer since April 2020 and as a Director on our Board since January 2020. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc. (acquired by Roche); President and Chief Executive Officer of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm; Chairman and Chief Executive Officer of Assembly Biosciences, Inc. (formerly Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, a global drug development and healthcare investment firm; Vice President of Clinical Development of FibroGen, Inc., where he played a key role in the early phase development of roxadustat in anemia for chronic kidney disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo US, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. in the United States. Dr. Ellison previously served as an Independent Board Director for several private and public companies, including Cougar Biotechnology Inc.; ProSanos Corporation; Cormedix Inc., a cardio-renal clinical stage company; and Mt. Cook, a urology-focused company. Dr. Ellison received a Master of Science degree from the London School of Tropical Medicine and Hygiene, and an M.D. from the University of British Columbia.

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.